ArticleCancer research2019
Abstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 85 citations in OpenAlex.
- ANKRD28 interacts with DOCK180 to activate Rac1-STAT3-Myc signaling and sustain stemness of CD34Molecular and cellular biochemistry · 2026Article
- Cancer Stem Cell Quiescence: Molecular and Microenvironmental Evidence for an Actively Regulated Adaptive Survival Strategy.Cancer medicine · 2026Review
- Exploring the Utility of ALDH1 as a Marker for the Cancer Stem Cell Population in OCCC Cell Lines.Cells · 2026Article
- The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia.Biomedicines · 2026Review
- Oncogene c‑Myc: From molecular mechanism to targeted therapy (Review).Molecular medicine reports · 2026Review
- Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer.Cell death & disease · 2026Article
- Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.Frontiers in cell and developmental biology · 2026Review
- Article
- Epigenetic reprogramming as the nexus of cancer stemness and therapy resistance: implications for biomarker discovery.Discover oncology · 2025Review
- Investigating the interaction of ACKR1 and c-Myc in the breast carcinoma tumor microenvironment modulation.Discover oncology · 2025Article
- Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression.Journal of experimental & clinical cancer research : CR · 2025Review
- NKD1 enhances colon cancer progression by inhibiting the autophagic degradation of MYC.Cell death & disease · 2025Article
- GATAD2B O-GlcNAcylation Regulates Breast Cancer Stem-like Potential and Drug Resistance.Cells · 2025Article
- Inhibition of the Hippo pathway by verteporfin reduces the proliferation and stemness of rat hair follicle neural crest stem cells under hypoxia.FASEB bioAdvances · 2025Article
- Review
- CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.Breast cancer research : BCR · 2025Article
- Review
- HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.Cell death discovery · 2024Article
- Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review).International journal of oncology · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Bikul DasDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California. dfelsher@stanford.edu bdas@kavikrishnalab.org.
Bidisha PalDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
Rashmi BhuyanDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-8614-6515
Hong LiDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California.
Anupam SarmaDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.ORCID 0000-0001-8631-2651
Sukanya GayanDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
Joyeeta TalukdarDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
Sorra SandhyaDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
Seema BhuyanDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.ORCID 0000-0002-8614-6515
Gayatri GogoiDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.
Arvin M GouwDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California.
Debabrat BaishyaDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India.ORCID 0000-0002-2929-8539
Jason R GotlibDivision of Hematology, Stanford Cancer Institute, Stanford, California.
Amal C KatakiDr. B. Borooah Cancer Institute, Guwahati, Assam, India.
Dean W FelsherDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California. dfelsher@stanford.edu bdas@kavikrishnalab.org.
Indian Institute of Technology Guwahati · INStanford Medicine · USBhubaneswar Borooah Cancer Institute · INCancer Prevention Institute of California · USUniversity of Massachusetts Lowell · US
Funding
MYC's Role in the Initiation and Maintenance of CancerR01CA089305 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2001 to 2011
$3.7MModeling and Predicting Therapeutic Resistance of CancerU01CA188383 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, GAMBHIR, SANJIV S · 2014 to 2018
$3.2MComputational Modeling of Cancer BiologyU56CA112973 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2004 to 2009
$2.9MMechanisms by which Oncogene Inactivation Elicits Tumor Cell DeathR01CA170378 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2012 to 2015
$2.1MMolecular and Cellular Basis of Oncogene AddictionR01CA105102 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2004 to 2010
$2.0MCancer-Translational Nanotechnology Training Program (Cancer-TNT)T32CA196585 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, RAO, JIANGHONG · 2015 to 2019
$1.8MNCI NIH HHS R01 CA089305NCI NIH HHS R01 CA105102NCI NIH HHS R01 CA170378NCI NIH HHS T32 CA196585NCI NIH HHS U01 CA188383NCI NIH HHS U56 CA112973
Abstract
Cancer stem cells (CSC) maintain both undifferentiated self-renewing CSCs and differentiated, non-self-renewing non-CSCs through cellular division. However, molecular mechanisms that maintain self-renewal in CSCs versus non-CSCs are not yet clear. Here, we report that in a transgenic mouse model of MYC-induced T-cell leukemia, MYC, maintains self-renewal in Sca1
Indexed as
AnimalsAntigens, LyATP Binding Cassette Transporter, Subfamily G, Member 2Basic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Gene Expression Regulation, NeoplasticHumansMembrane ProteinsMice, SCIDMice, TransgenicNanog Homeobox ProteinNeoplasm ProteinsNeoplastic Stem CellsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPromoter Regions, GeneticProto-Oncogene Proteins c-mycABCG2 protein, humanAntigens, LyATP Binding Cassette Transporter, Subfamily G, Member 2Basic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Ly6a protein, mouseMembrane ProteinsNanog Homeobox ProteinNANOG protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-mycReactive Oxygen SpeciesSOX2 protein, humanSOXB1 Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.